Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype (Q35182598)

7 August 2017

title

Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype (English)

1 reference

7 August 2017

1 reference

Metaplastic carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

Fernando Schmitt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

Fernando Schmitt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

António E Pinto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Saudade André

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

publication date

6 June 2014

1 reference

7 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

465

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

185-191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24903673 AND SRC:MED&resulttype=core&format=json

Low-grade (fibromatosis-like) spindle cell carcinoma of the breast

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Metaplastic breast carcinomas are basal-like tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Deconstructing the molecular portraits of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Low-grade fibromatosis-like spindle cell metaplastic carcinoma of the breast: a case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

The p53 pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00428-014-1603-9

An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast

21 January 2018

1 reference

12 December 2020

Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice

1 reference

12 December 2020

Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence

1 reference

12 December 2020

[Metaplastic spindle-cell (fibromatosis-like) carcinoma of the breast--report of 4 cases]

1 reference

12 December 2020

Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition

1 reference

12 December 2020

Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumor with a favorable clinical outcome. Report of two cases.

1 reference

12 December 2020

Immunohistochemical study of p53 and Ki67 in a group of patients with mammary carcinoma

1 reference

12 December 2020